The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The main objectives of this study are to evaluate the efficacy and safety of combination
therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol
and other lipoproteins over 12 weeks of therapy.